

CLAIMS

1. A compound of general formula (IB):



~~(I)~~



(IB)

wherein:

each $R^1$ is independently halo, ~~OH, cyano, nitro,~~ $NR^{10}R^{11}$, ~~$C(O)R^{10}$, $C(O)OR^{10}$, $C(O)NR^{10}R^{11}$, $-S(O)_qNR^{10}R^{11}$,~~ $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, $-O(C_{1-6}$ alkyl), $-O(C_{1-6}$ haloalkyl), aryl, heteroaryl, -O-aryl or -O-heteroaryl,

wherein

each $R^{10}$ and $R^{11}$ is independently selected from H or $C_{1-6}$ alkyl; ~~optionally substituted with one or more substituents selected from OH, halo, cyano, $NH_2$, aryl or heteroaryl;~~

~~alkyl and haloalkyl groups $R^1$ are optionally substituted with one or more substitutents selected from OH, cyano, $-S(O)_pNR^4R^5$, $-C(O)NR^4R^5$, aryl, heteroaryl, -O-aryl or -O-heteroaryl $-O(C_{1-6}$ alkyl) optionally substituted with aryl or $-O(C_{1-6}$ haloalkyl);~~

aryl or heteroaryl groups $R^1$ are optionally substituted with one or more substituents selected from halo, OH, cyano, nitro, $-NR^4R^5$, $-S(O)_pNR^4R^5$, $-C(O)NR^4R^5$, ~~$-C(O)R^4$, $-C(O)OR^4$ or~~ $-C_{1-6}$ alkyl, or $-O(C_{1-6}$ alkyl), wherein either of the $-C_{1-6}$ alkyl, or $-O(C_{1-6}$ alkyl) groups are ~~which is~~ optionally substituted with one or more substituents

selected from OH, halo, aryl, heteroaryl, -O($C_{1-6}$ alkyl), or O($C_{1-6}$ haloalkyl), -O-aryl or –O-heteroaryl);

p is 1 or 2;

each $R^4$ and $R^5$ is independently selected from H or $C_{1-4}$ alkyl or $R^4$ and $R^5$ together with a nitrogen atom to which they are attached may form a 3- or 8-membered heterocyclic ring, optionally containing one or more additional heteroatoms selected from O, N and S;

n is 0, 1, 2, 3, or 4, or 5;

$R^{2a}$ and $R^{2b}$ are each independently $C_{1-6}$ alkyl optionally substituted with one or more substituents selected from halo, OH, aryl or heteroaryl; or

$R^{2a}$ and $R^{2b}$ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring optionally containing one or more further heteroatoms selected from O, N or S and optionally substituted with one or more substituents $R^6$;

each $R^6$ is independently selected from aryl, substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, -O($C_{1-4}$ alkyl) and -O($C_{1-4}$ haloalkyl); heteroaryl, selected from indolyl, isoindolyl, benzoxazolyl and benzisoxazolyl and optionally substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, -O($C_{1-4}$ alkyl) and -O($C_{1-4}$ haloalkyl); -O-aryl, substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, -O($C_{1-4}$ alkyl) and -O($C_{1-4}$ haloalkyl); -O-heteroaryl, selected from indolyl, isoindolyl, benzoxazolyl and benzisoxazolyl and optionally substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, -O($C_{1-4}$ alkyl) and -O($C_{1-4}$ haloalkyl); and $C_{1-4}$ alkyl substituted with two aryl or two heteroaryl groups, wherein at least one of the aryl and heteroaryl groups is substituted with one or more substituents selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, -O($C_{1-4}$ alkyl) and -O($C_{1-4}$ haloalkyl); carbocyclyl, heterocyclyl, -O-carbocyclyl, -O-heterocyclyl, $R^{12}$, $OR^{12}$, $C(O)R^{12}$, $C(O)OR^{11}$, $C(O)NR^{11}R^{12}$, CN,OH,

each $R^{11}$ and $R^{12}$ is independently H or $C_{1-4}$ alkyl, either or which may be substituted with one or more aryl or heteroaryl groups, wherein aryl and heteroaryl groups are substituted with one or more substituent selected from halo, OH, cyano, nitro, $NR^4R^5$, $S(O)_pNR^4R^5$, $C(O)NR^4R^5$, $C(O)R^4$, $C(O)OR^4$ or $C_{1-6}$ alkyl or -O($C_{1-6}$ alkyl) , either of which is optionally substituted with one or more substituents selected from OH, halo, aryl, heteroaryl, -O($C_{1-6}$ alkyl), O($C_{1-6}$ haloalkyl), -O-aryl or –O-heteroaryl);

wherein $R^4$ and $R^5$ are as defined above; or $R^{11}$ and $R^{12}$ may combine with a nitrogen atom to which they are attached to form a 3 to 8-membered heterocyclic


~~ring optionally containing one or more further heteroatoms selected from N, O and S and optionally substitututed with $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl or halo;~~

$R^3$ is aryl~~,~~ or heteroaryl~~, carbocyclyl or heterocyclyl~~ any of which is optionally substituted with one or more substituents $R^7$ selected from halo, -$C_{1-4}$ alkyl optionally substituted with aryl, -O($C_{1-4}$ alkyl) optionally substituted with aryl, -$C_{1-4}$ haloalkyl, -O($C_{1-4}$ haloalkyl) or -C(O)$NR^8R^9$;


each $R^8$ and $R^9$ is independently selected from H, $C_{1-4}$ alkyl or $C_{3-6}$ cycloalkyl or $R^8$ and $R^9$ together with the nitrogen atom to which they are attached may form a 5- or 6-membered heterocyclic ring, optionally containing one or more additional heteroatoms selected from O, N and S;

or a pharmaceutically acceptable salt, solvate or hydrate thereof or a deuterated or tritiated variant thereof, including all stereoisomers.

2. A compound according to claim 1, wherein $R^3$ is phenyl optionally substituted with one or more substituents $R^7$ such that the compound of general formula (IB) is a compound of general formula (~~IA~~ ID):




~~(IA)~~




(ID)

wherein~~:~~ z is 0 to 5

each $R^1$ is independently halo, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, aryl or heteroaryl, wherein aryl or heteroaryl groups are optionally substituted with one or more substituents selected from halo, OH, cyano, nitro, $-S(O)_pNR^4R^5$, $-C(O)NR^4R^5$, $-C_{1-6}$ alkyl optionally substituted with aryl, $-C_{1-6}$ haloalkyl, $-O(C_{1-6}$ alkyl) optionally substituted with aryl or $-O(C_{1-6}$ haloalkyl);

p is 0, 1 or 2;

each $R^4$ and $R^5$ is independently selected from H or $C_{1-4}$ alkyl or $R^4$ and $R^5$ together with the nitrogen atom to which they are attached may form a 5- or 6-membered heterocyclic ring, optionally containing one or more additional heteroatoms selected from O, N and S;

m is 0, 1, 2, 3 or 4;

$R^{2a}$ and $R^{2b}$ are each independently $C_{1-6}$ alkyl optionally substituted with one or more substituents selected from halo, OH, aryl or heteroaryl; or

$R^{2a}$ and $R^{2b}$ together with the nitrogen atom to which they are attached form a 5- or 6-membered heterocyclic ring optionally containing one or more further heteroatoms selected from O, N or S and optionally substituted with one or more substituents $R^6$;

each $R^6$ is independently selected from aryl, heteroaryl, -O-aryl, -O-heteroaryl or $C_{1-4}$ alkyl substituted with one or more aryl or heteroaryl groups, wherein aryl and heteroaryl groups are substituted with one or more substituent selected from halo, $C_{1-4}$ alkyl, $C_{1-4}$ haloalkyl, $-O(C_{1-4}$ alkyl) or $-O(C_{1-4}$ haloalkyl);

$R^3$ is aryl, heteroaryl, carbocyclyl or heterocyclyl any of which is optionally substituted with one or more substituents $R^7$ selected from halo, $-C_{1-4}$ alkyl optionally substituted with aryl, $-O(C_{1-4}$ alkyl) optionally substituted with aryl, $-C_{1-4}$ haloalkyl, $-O(C_{1-4}$ haloalkyl) or $-C(O)NR^8R^9$;

each $R^8$ and $R^9$ is independently selected from H, $C_{1-4}$ alkyl or $C_{3-6}$ cycloalkyl or $R^8$ and $R^9$ together with the nitrogen atom to which they are attached may form a 5- or 6-membered heterocyclic ring, optionally containing one or more additional heteroatoms selected from O, N and S;

or a pharmaceutically acceptable salt, solvate or hydrate thereof or a deuterated or tritiated variant thereof, including all stereoisomers.

3. A compound according to claim 1, wherein n is 0 1 or 2 and at least one $R^1$ group is OH; or a compound according to claim 2 wherein m is 0 or 1.


4. A compound according to claim 2 or claim 3 1, wherein m n is other than 0 and $R^1$ is halo or an aryl or heteroaryl group optionally substituted as defined in claim 2 1.

5. A compound according to claim 4, wherein $R^1$ is an aryl or heteroaryl group optionally substituted with halo, OH, cyano, nitro, $-SO_2NH_2$, $-C(O)NR^4R^5$, $-C_{1-4}$ alkyl optionally substituted with aryl, $-C_{1-4}$ haloalkyl, $-O(C_{1-4}$ alkyl) optionally substituted with aryl or $-O(C_{1-4}$ haloalkyl), where $R^4$ and $R^5$ together with the nitrogen atom to which they are attached form a piperidine or pyrrolidine ring.

6. A compound according to claim 5, wherein $R^1$ is an aryl or heteroaryl group optionally substituted with chloro, fluoro, methyl, ethyl, trifluoromethyl, benzyl, methoxy, ethoxy, benzyloxy, trifluoromethoxy ~~and~~ or piperidine-1-carbonyl.

7. A compound according to ~~any one of claims 1 to 6~~ claim 1, wherein $R^3$ is heteroaryl optionally substituted with one or more substituents $R^7$ selected from halo, $-C_{1-4}$ alkyl optionally substituted with aryl, $-O(C_{1-4}$ alkyl) optionally substituted with aryl, $-C_{1-4}$ haloalkyl, $-O(C_{1-4}$ haloalkyl) or $-C(O)NR^8R^9$; wherein each $R^8$ and $R^9$ is independently selected from H, $C_{1-4}$ alkyl or $C_{3-6}$ cycloalkyl or $R^8$ and $R^9$ together with the nitrogen atom to which they are attached may form a 5- or 6-membered heterocyclic ring, optionally containing one or more additional heteroatoms selected from O, N and S. ~~$R^{2a}$ and $R^{2b}$ together with the nitrogen atom to which they are attached form a 6-membered heterocyclic ring optionally substituted with one or more substituents $R^6$.~~

8. A compound according to claim ~~7~~ 1 ~~wherein $R^{2a}$ and $R^{2b}$ together with the nitrogen atom to which they are attached form a a piperazine ring substituted by a single $R^6$ substituent at the piperazine 4-position such that the compound of general formula (I) is a compound of general formula (IB):~~




~~(IB)~~


~~wherein $R^1$, n, $R^3$ and $R^6$ are as defined in claim 2.~~

wherein each $R^1$ is independently halo, $C_{1-6}$ alkyl, $C_{1-6}$ haloalkyl, aryl or heteroaryl, wherein aryl or heteroaryl groups are optionally substituted with one or more substituents selected from halo, OH, cyano, nitro, $-S(O)_pNR^4R^5$, $-C(O)NR^4R^5$, $-C_{1-6}$ alkyl optionally substituted with aryl, $-C_{1-6}$ haloalkyl, $-O(C_{1-6}$ alkyl) optionally substituted with aryl or $-O(C_{1-6}$ haloalkyl);


p is 0, 1 or 2;

each $R^4$ and $R^5$ is independently selected from H or $C_{1-4}$ alkyl or $R^4$ and $R^5$ together with the nitrogen atom to which they are attached may form a 5- or 6-membered heterocyclic ring, optionally containing one or more additional heteroatoms selected from O, N and S.

9. A compound according to ~~any one of claims 1 to 8~~ claim 1, wherein $R^6$ is phenyl, ~~heteroaryl, -O-phenyl, -O heteroaryl, benzyl, -CH(phenyl)$_2$, -CH$_2$-heteroaryl and~~ or –CH(heteroaryl)$_2$, where the heteroaryl group is selected from pyridinyl, indolyl, isoindolyl, benzoxazolyl and benzisoxazolyl, and wherein any of the above $R^6$ groups may be substituted as defined in claim 1.

10. A compound according to ~~any one of claims 1 to 9~~ claim 1, wherein $R^6$ is 

. ~~$R^3$ is phenyl optionally substituted with one or more substituents $R^7$ such that the compound of general formula (I) is a compound of general formula (IC):~~





~~(IC)~~

~~wherein $R^1$, n, $R^{2a}$, $R^{2b}$ and $R^7$ are as defined for general formula (I) and z is 0 to 5.~~

11. A compound according to claim ~~10~~ 2, wherein z is 0, 1 or 2; $R^7$ ~~not present (i.e. z is 0)~~ is absent, or $R^7$ is halo, $-C_{1-4}$ alkyl, benzyl, $-O(C_{1-4}$ alkyl), benzyloxy, $-C_{1-4}$ haloalkyl, $-O(C_{1-4}$ haloalkyl) or $-C(O)NR^8R^9$, where $R^8$ and $R^9$ together with the nitrogen atom to which they are attached form a piperidinyl ring or wherein $R^8$ is H and $R^9$ is ~~$C_{3-7}$~~ $C_{3-6}$ cycloalkyl.


~~11.~~12. A compound according to ~~any one of claims 1 to 10~~ claim 2, ~~which is a compound of general formula (ID):~~



~~(ID)~~

wherein ~~$R^1$, n, $R^6$,~~ z is 1, $R^7$ is C(O)$NR^8R^9$, $R^8$ is H and $R^9$ is $C_{3-6}$ cycloalkyl. ~~and z are as defined above.~~


13. A compound of claim 12 selected from the group consisting of:




,





,







,







,














































, 


, and 


,

or a pharmaceutically acceptable salt, solvate or hydrate thereof or a deuterated or tritiated variant thereof, including all stereoisomers.

~~12.~~14. A compound ~~according to claim 1~~ selected from:

2-((2-chlorophenyl)(4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenol (Compound 1);

2-((4-chlorophenyl)(4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenol (Compound 2);

2-((4-(benzyloxy)-3-fluorophenyl)(4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenol (Compound 3);

(4-((2-hydroxyphenyl)(4-(4-Methoxyphenyl)piperazinyl)methyl)phenyl)(piperidin-1-yl)methanone (Compound 4);

3-((5-chloro-2-hydroxyphenyl)(4-(4-methoxyphenyl)piperazin-1-yl)methyl)-N-cyclopentylbenzamide (Compound 5);

2-((4-(benzyloxy)-3-fluorophenyl)(4-(4-methoxyphenyl)piperazin-1-yl)methyl)-4-chlorophenol (Compound 6);

~~2-((4-(benzyloxy)-3-fluorophenyl)(4-(6-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)methyl)phenol (Compound 7);~~

2-((4-(2, 3-dichlorophenyl)piperazin-1-yl)(o-tolyl)methyl)phenol (Compound 8);

N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(2-hydroxyphenyl)methyl) benzamide (Compound 9, NPB);

2-((4-(benzyloxy)-3-fluorophenyl)(4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)phenol (Compound 10);

2-((4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)(phenyl)methyl)phenol (Compound 11);
2-((4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)(p-tolyl)methyl)phenol (Compound 12);
2-((4-chlorophenyl)(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)methyl)phenol (Compound 13);
2-((4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)(4-ethylphenyl)methyl)phenol (Compound 14);
(4-((4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)(2-hydroxyphenyl)methyl)phenyl) (piperidin-1-yl)methanone (Compound 15);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 16);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-2'-methyl-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 17);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-3'-methyl-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 18);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-4'-methyl-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 19);
3-((2'-chloro-4-hydroxy-[1,1'-biphenyl]-3-yl)(4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-N-cyclopentylbenzamide (Compound 20);
3-((3'-chloro-4-hydroxy-[1,1'-biphenyl]-3-yl)(4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-N-cyclopentylbenzamide (Compound 21);
3-((4'-chloro-4-hydroxy-[1,1'-biphenyl]-3-yl)(4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-N-cyclopentylbenzamide (Compound 22);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4'-ethyl-4-hydroxy-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 23);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-4'-(piperidine-1-carbonyl)-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 24);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-4'-methoxy-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 25);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(2'-ethyl-4-hydroxy-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 26);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(2'-fluoro-4-hydroxy-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 27);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(3'-fluoro-4-hydroxy-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 28);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4'-fluoro-4-hydroxy-[1,1'-

biphenyl]-3-yl)methyl)benzamide (Compound 29);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-3'-nitro-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 30);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-3'-sulfamoyl-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 31);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-2'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 32);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-3'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 33);
N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-hydroxy-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)methyl)benzamide (Compound 34);
3-((2'-cyano-4-hydroxy-[1,1'-biphenyl]-3-yl)(4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-N-cyclopentylbenzamide (Compound 35);
3-((3'-cyano-4-hydroxy-[1,1'-biphenyl]-3-yl)(4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-N-cyclopentylbenzamide (Compound 36)
3-((4'-cyano-4-hydroxy-[1,1'-biphenyl]-3-yl)(4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-N-cyclopentylbenzamide (Compound 37);
3-((2'-chloro-4-hydroxy-4'-(trifluoromethyl)-[1,1'-biphenyl]-3-yl)(4-(2,3-dichlorophenyl) piperazin-1-yl)methyl)-N-cyclopentylbenzamide (Compound 38);
N-cyclopentyl-3-((2',4'-dichloro-4-hydroxy-[1,1'-biphenyl]-3-yl)(4-(2,3-dichlorophenyl) piperazin-1-yl)methyl)benzamide (Compound 39);
3-((4'-chloro-2',4-dihydroxy-[1,1'-biphenyl]-3-yl)(4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-N-cyclopentylbenzamide (Compound 40);
3-((4-(4-chlorophenyl)piperazin-1-yl)(2-hydroxyphenyl)methyl)-N-cyclopentylbenzamide (Compound 41, NCK1)
2-((4-chlorophenyl)(4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)phenol (Compound 42, NCK2)
2-((4-(2,3-dichlorophenyl)piperazin-1-yl)(3-methoxyphenyl)methyl)phenol (Compound 43, NCK3)
1-(5-((4-(2,3-dichlorophenyl)piperazin-1-yl)(2-hydroxyphenyl)methyl)thiophen-2-yl)ethanone (Compound 44, NCK4)
2-((4-(2,3-dichlorophenyl)piperazin-1-yl)(naphthalen-1-yl)methyl)phenol (Compound 45, NCK5)
5-((4-(2,3-dichlorophenyl)piperazin-1-yl)(2-hydroxyphenyl)methyl)furan-2-carbaldehyde (Compound 46, NCK6)
2-((4-(~~5,6-dichlorocyclohexa-1,5-dien-1-yl~~2,3-dichlorophenyl)piperazin-1-yl)(2-fluoro-3-methylpyridin-4-yl)methyl)phenol (Compound 47, NCK7)

2-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-(trifluoromethyl)phenyl)methyl)phenol (Compound 48, NCK8)

2-((6-chloro-5-methylpyridin-3-yl)(4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)phenol (Compound 49, NCK9)

2-((4-(2,3-dichlorophenyl)piperazin-1-yl)(pyridin-3-yl)methyl)phenol (Compound 50, NCK10)

1-(5-((4-(4-chlorophenyl)piperazin-1-yl)(2-hydroxyphenyl)methyl)thiophen-2-yl)ethanone (Compound 51, NCK14)

3-((4-(4-chlorophenyl)piperazin-1-yl)(4-(diethylamino)-2-hydroxyphenyl)methyl)-N-cyclopentylbenzamide(Compound 52, NCK16)

N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(4-(diethylamino)-2-hydroxyphenyl)methyl)benzamide (Compound 53, NCK18)

N-cyclopentyl-3-((4-(2,3-dichlorophenyl)piperazin-1-yl)(2-hydroxy-4,6-dimethoxyphenyl)methyl)benzamide (Compound 54, NCK19)

2-((4-chlorophenyl)(4-(4-chlorophenyl)piperazin-1-yl)methyl)phenol (Compound 55, NCK20)

2-((4-(4-chlorophenyl)piperazin-1-yl)(6-methylpyridin-3-yl)methyl)phenol (Compound 56, NCK21)

2-(o-tolyl(4-(p-tolyl)piperazin-1-yl)methyl)phenol (Compound 57, SG1)

2-((4-(p-tolyl)piperazin-1-yl)(4-(trifluoromethyl)phenyl)methyl)phenol (Compound 58, SG2)

N-cyclopentyl-4-((2-hydroxyphenyl)(4-(p-tolyl)piperazin-1-yl)methyl)benzamide (Compound 59, SG3)

2-((4-chlorophenyl)(4-(p-tolyl)piperazin-1-yl)methyl)phenol (Compound 60, SG4)

2-((3-methoxyphenyl)(4-(p-tolyl)piperazin-1-yl)methyl)phenol (Compound 61, SG5)


5-((2-hydroxyphenyl)(4-(p-tolyl)piperazin-1-yl)methyl)furan-2-carbaldehyde (Compound 62, SG6)

2-((6-methylpyridin-3-yl)(4-(p-tolyl)piperazin-1-yl)methyl)phenol (Compound 63, SG7);

or a pharmaceutically acceptable salt, solvate or hydrate thereof or a deuterated or tritiated variant thereof, including all stereoisomers.

~~14. A process for the preparation of a compound according to any one of claims 1 to 13 which comprises either:~~


~~i. reacting an aldehyde of general formula (II):~~



(II)

wherein $R^1$ and n are as defined in claim 1;


with a compound of general formula (III):



(III)

wherein $R^{2a}$ and $R^{2b}$ are as defined in claim 1;


and a boronic acid of general formula (IV):



(IV)

wherein $R^3$ is as defined in claim 1; or

ii. reacting a compound of general formula (I) in which $R^1$ is halo with a compound of general formula (V):



(V)

wherein $R^{1a}$ is aryl or heteroaryl optionally substituted as defined for $R^1$ in claim 1;

via a Suzuki coupling reaction in the presence of a palladium catalyst to obtain a compound of general formula (I) in which $R^1$ is $R^{1a}$.

15. A compound according to any one of claims 1 to 13 for use in medicine.

16. A compound according to any one of claims 1 to 13 for use in the treatment of cancer.

~~17. The use of a compound according to any one of claims 1 to 13 in the preparation of an agent for the treatment of cancer.~~

~~18. A method for the treatment of cancer, the method comprising administering to a patient in need of such treatment an effective amount of a compound according to any one of claims 1 to 13.~~

~~19. A compound for use, use or method according to any one of claims 16 to 18 wherein the cancer is a cancer in which there is BAD phosphorylation, for example breast cancer, endometrial cancer, ovarian cancer, liver cancer, colon cancer, prostate cancer or pancreatic cancer or any other epithelial derived cancer in which BAD is phosphorylated.~~

~~20.~~15. A pharmaceutical composition comprising a compound according to ~~any one of claims 1 to 13~~ claim 1 and a pharmaceutically acceptable excipient.

~~21.~~16. A pharmaceutical composition according to claim ~~20~~ 15 which is formulated for intraperitoneal administration, hepatoportal administration, intravenous administration, intra articular administration, pancreatic duodenal artery administration, ~~or~~ intramuscular administration, or any combination thereof.